Tolerance Bio is developing therapies to extend health span by preserving, restoring, and modulating thymic function - the master regulator of immune tolerance.We are advancing a multi-modal, clinical ...

NASDAQ:JUNS.2 businesses. 1, Biotech with platform product in Phase II in Parkinsons’s Disease.2. Nugevia.com nutritional oriduct line for Longevity & Aging. Launched in Q1 2026. Tru science in a fiek ...

Preload Therapeutics is pursuing cardiometabolic reprogramming via FGF21 agonism. Preload has in-licensed a late development ready asset: PTX-001 (aka NGM-313/MK-3655) —the only FGF21 agonist antibody ...

Syncromune, Inc. is developing a platform immunotherapy technology to treat metastatic solid tumor cancers, with its lead program demonstrating powerful clinical results in mCRPC patients with planned ...

Boston Capital Investment Club (BCIC) operates the largest asian biotech startup communities in the US. We are strategic partner with Hong Kong Science and Technology Parks Corporation, Roche Accelera ...

CGP invests in innovations across the Life Sciences industry.Our target technologies are breakthroughs with unmet clinical need, strong IP protection, and the appeal to become a must-have for strategi ...

Eleva is a clinical-stage biopharmaceutical company that strives to bring novel therapies to patients with serious unmet medical needs. Our unique moss-based platform opens new possibilities for expre ...